Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies

The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer

(2012) Madhu S. Kumar et al.   CELL

STK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells

(2011) C. Babij et al.   CANCER RESEARCH

Response and Resistance to NF- B Inhibitors in Mouse Models of Lung Adenocarcinoma

(2011) W. Xue et al.   Cancer Discovery

Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner

(2010) O. Gilad et al.   CANCER RESEARCH

Linking mitosis with S-phase: Cdc6 at play

(2010) Susanna Boronat et al.   CELL CYCLE

CDC6 interaction with ATR regulates activation of a replication checkpoint in higher eukaryotic cells

(2010) K. Yoshida et al.   JOURNAL OF CELL SCIENCE

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

(2010) Angela M. Davies et al.   Journal of Thoracic Oncology

Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells

(2010) Y Wang et al.   ONCOGENE

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

(2009) Claudia Scholl et al.   CELL

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

(2009) Ji Luo et al.   CELL

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma

(2009) Etienne Meylan et al.   NATURE